CompletedPhase 4ACTRN12619001231134

The effect of Colchicine on the release of Neutrophil Extra-cellular Traps after Percutaneous Coronary Intervention in Acute Coronary Syndrome Patients..


Sponsor

Sanjay Patel

Enrollment

60 participants

Start Date

Jan 22, 2016

Study Type

Interventional

Conditions

Summary

Percutaneous coronary intervention (PCI) in acute coronary syndrome (ACS) patients is associated with a higher incidence of peri-procedural myocardial infarction. An increased release of neutrophil-derived inflammatory products is known to contribute to this process. Colchicine is a well-established anti-inflammatory drug, however its role in attenuating post-PCI release of activated neutrophil-mediators is not well known. This pilot study aims to investigate whether peri-procedural colchicine would suppress local release of Neutrophil Extracellular Traps, and its components Human Neutrophil Elastase and Myeloperoxidases, in both ACS and stable angina pectoris patients.


Eligibility

Sex: Both males and femalesMin Age: 18 Yearss

Inclusion Criteria1

  • Patients with clinical indication for coronary angiogram and percutaneous coronary intervention.

Exclusion Criteria6

  • Patients with >50% Left main artery stenosis
  • Patients with cardiogenic shock
  • Patients with haemodynamic instability
  • Patients currently lactating
  • Patients with known colchicine hypersensitivity
  • Patients already taking colchicine before the procedure.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

All colchicine administered was administered 6 to 24 hours prior to coronary angiography. This is due to uncertainty in waiting time for the angiogram depending on the angiogram list. Within this 6-2

All colchicine administered was administered 6 to 24 hours prior to coronary angiography. This is due to uncertainty in waiting time for the angiogram depending on the angiogram list. Within this 6-24 hour window, the treatment group received TWO doses of colchicine. The first dose was a 1 mg oral tablet. After receiving this first dose, the second dose was a 0.5 mg oral tablet given 1 hour later. Hence all treatment group patients received 1.5mg of colchicine in total. Colchicine was administered in alternating fashion, with every other patient receiving no colchicine. All patients underwent coronary angiogram.


Locations(1)

Royal Prince Alfred Hospital - Camperdown

NSW, Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12619001231134


Related Trials